Lantern Pharma Inc. Files 8-K on Shareholder Vote
Ticker: LTRN · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Lantern Pharma held a shareholder vote on June 13th, filed the 8-K on June 17th.
AI Summary
Lantern Pharma Inc. filed an 8-K on June 17, 2024, reporting on a matter submitted to a vote of security holders on June 13, 2024. The filing details the company's principal executive offices located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas.
Why It Matters
This filing indicates a formal process involving shareholder decisions, which can impact corporate governance and future strategic directions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Lantern Pharma Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- June 17, 2024 (date) — Date of report
- 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 (location) — Principal Executive Offices
FAQ
What specific matter was submitted to a vote of security holders?
The filing states that a matter was submitted to a vote of security holders, but the specific details of the vote are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 13, 2024.
What is the principal executive office address for Lantern Pharma Inc.?
The principal executive office is located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201.
What is the SEC file number for Lantern Pharma Inc.?
The SEC file number is 001-39318.
What is the fiscal year end for Lantern Pharma Inc.?
The fiscal year end for Lantern Pharma Inc. is December 31.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-06-17 16:15:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value LTRN The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 45KB
- 0001493152-24-024110.txt ( ) — 218KB
- ltrn-20240613.xsd (EX-101.SCH) — 3KB
- ltrn-20240613_lab.xml (EX-101.LAB) — 33KB
- ltrn-20240613_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lantern Pharma Inc., A Delaware Corporation Dated: June 17, 2024 By: /s/ David R. Margrave David R. Margrave, Chief Financial Officer 3